GO:0043697 cell dedifferentiation: Regenerative Plasticity, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0043697 cell dedifferentiation describes the process by which a specialized cell loses its mature structural or functional features and can revert toward a stem-cell-like state.
• Dedifferentiation is a physiological regeneration mechanism, as shown by Ascl2-dependent dedifferentiation of intestinal cells after stem cell ablation.
• In pancreatic islets, loss of β-cell identity and dedifferentiation contributes to diabetic β-cell failure and is not necessarily irreversible.
• Dedifferentiation is driven by transcriptional, metabolic and epigenetic reprogramming, including factors such as Ascl2, SMOC1 and LDHA.
• Transcriptomic features of dedifferentiation are actively debated as a mechanism in cancer biology.
• CRISPR knockout, point-mutation, knock-in and overexpression models allow causal testing of dedifferentiation genes in relevant cell types.
Description
Cell dedifferentiation (GO:0043697) is a biological process in which a specialized cell loses the structural or functional features that characterize it in the mature organism or another relatively stable phase of its life history, and under certain conditions can revert toward the features of ancestral stem cells. This process is central to regenerative responses, because ablated stem cell pools can be replenished by dedifferentiation of more differentiated cells. It is also a mechanism of disease, most prominently in diabetes, where pancreatic β cells lose their identity and dedifferentiate, contributing to β-cell failure. Because dedifferentiation sits at the intersection of regeneration, metabolic disease and cancer, researchers need precise definitions, validated markers and causal models to study it. This article summarizes the QuickGO definition of GO:0043697, the genes and mechanisms reported in the literature, and the experimental methods used to investigate cell dedifferentiation.
cell dedifferentiation At A Glance
| GO ID | GO:0043697 |
|---|---|
| GO term | cell dedifferentiation |
| Ontology | biological_process |
| Synonym | none listed in QuickGO |
| Major function | Loss of specialized structural or functional features with potential reversion toward ancestral stem-cell features |
| Representative context | Intestinal stem cell regeneration after ablation |
| Disease relevance | Pancreatic β-cell failure in diabetes |
| Key regulators | Ascl2, SMOC1, LDHA and other reprogramming factors |
| Research models | CRISPR knockout, point mutation, knock-in and overexpression cell models |
What Is GO:0043697?
According to the QuickGO definition, cell dedifferentiation (GO:0043697) is the process in which a specialized cell loses the structural or functional features that characterize it in the mature organism, or some other relatively stable phase of the organism's life history. Under certain conditions, these cells can revert back to the features of the stem cells that were their ancestors. In practice, this means a cell that has acquired a mature identity can downregulate lineage-specific programs and re-express stem or progenitor-associated programs.
Why Is cell dedifferentiation Important in Cell Biology?
Cell dedifferentiation is important because it can restore lost cell populations after injury, yet the same plasticity can drive pathological loss of cell identity in diabetes and contribute to cancer biology. Understanding GO:0043697 therefore informs regenerative medicine, diabetes research and oncology, and requires causal experiments rather than correlative marker studies.
• Provides a regenerative mechanism when resident stem cells are ablated, as shown for intestinal stem cells.
• Explains loss of β-cell identity in diabetes and supports the idea that this state may be reversible.
• Links metabolic and epigenetic reprogramming to loss of differentiated function.
• Identifies candidate dedifferentiation genes such as SMOC1 through trajectory inference in human islets.
• Raises the question of whether dedifferentiation features overlap with cancer transcriptomes.
• Requires careful definition because dedifferentiation is distinct from simple cell death or transdifferentiation.
• Offers therapeutic targets if dedifferentiated cells can be redifferentiated.
• Can be modeled with CRISPR knockout, point mutation, knock-in and overexpression in relevant cell lines.
What Happens During cell dedifferentiation?
Trigger and loss of mature identity
In simple terms: A mature cell first receives a stress or injury signal that tells it to stop acting like a specialized cell.
Dedifferentiation begins when a specialized cell loses the structural or functional features that characterize its mature state. In the intestine, ablation of stem cells triggers dedifferentiation of more differentiated cells to regenerate the stem cell pool. In pancreatic β cells, loss of β-cell identity is observed under diabetic conditions and is described as dedifferentiation rather than an irreversible loss.
Transcriptional reprogramming
In simple terms: The cell rewires which genes are switched on and off, turning down mature genes and turning up stem-like genes.
Transcriptional reprogramming is a core step of dedifferentiation. Ascl2-dependent cell dedifferentiation drives regeneration of ablated intestinal stem cells, showing that a specific transcription factor can be required for this process. Trajectory inference analyses in human pancreatic α cells identified SMOC1 as a β-cell dedifferentiation gene, linking transcriptional state changes to dedifferentiation.
Metabolic and epigenetic reprogramming
In simple terms: Changes in how the cell uses energy can also change which genes are accessible, helping the cell shift identity.
LDHA induces beta cell dedifferentiation in diabetes through metabolic and epigenetic reprogramming, indicating that metabolic enzymes can drive dedifferentiation by altering epigenetic states. This connects dedifferentiation to cellular metabolism and chromatin regulation rather than to transcription factors alone.
Reversion toward stem-cell features
In simple terms: If conditions allow, the cell can regain features of the stem cells it came from.
Under certain conditions, dedifferentiated cells can revert back to the features of the stem cells that were their ancestors, as stated in the GO:0043697 definition. In diabetes research, loss of β-cell identity and dedifferentiation are discussed as not an irreversible process, suggesting that redifferentiation may be possible.
Resolution: regeneration or pathology
In simple terms: The outcome depends on context: dedifferentiation can rebuild tissue or contribute to disease.
In intestinal regeneration, dedifferentiation restores ablated stem cells. In diabetes, β-cell dedifferentiation is a mechanism of diabetic β-cell failure. In cancer biology, dedifferentiation features are debated as part of the evolutionary reversal theory of cancer. The same process can therefore be beneficial or harmful depending on the tissue and trigger.
Key Genes Involved in GO:0043697 cell dedifferentiation
The following genes and proteins have been reported in the literature on cell dedifferentiation (GO:0043697) and related regenerative or diabetic contexts.
| Gene | Major Role | Research Relevance |
|---|---|---|
| Ascl2 | Transcription factor required for dedifferentiation-driven intestinal stem cell regeneration | Causal knockout and overexpression models for regeneration |
| SMOC1 | Identified as a β-cell dedifferentiation gene by trajectory inference in human α cells | Candidate target for islet dedifferentiation studies |
| LDHA | Induces beta cell dedifferentiation via metabolic and epigenetic reprogramming | Metabolic-epigenetic axis in diabetes models |
| INS | β-cell identity marker whose loss accompanies dedifferentiation | Marker of β-cell identity in dedifferentiation assays |
| GCG | α-cell marker used in islet heterogeneity and trajectory analyses | Lineage and trajectory inference in human islets |
| PDX1 | β-cell identity factor discussed in loss of β-cell identity | Readout of β-cell dedifferentiation |
| NKX6.1 | β-cell identity factor discussed in dedifferentiation | Readout of β-cell dedifferentiation |
| FOXO1 | Signaling factor implicated in β-cell dedifferentiation mechanisms | Genetic models of diabetic β-cell failure |
| MAFA | β-cell maturation factor whose loss is associated with dedifferentiation | Marker of mature β-cell state |
| OCT4 | Pluripotency-associated factor used as a stem-like marker in dedifferentiation concepts | Transcriptomic comparison in cancer dedifferentiation debates |
| SOX2 | Stem-like marker relevant to dedifferentiation states | Transcriptomic feature comparison |
| KLF4 | Stem-like factor relevant to dedifferentiation states | Transcriptomic feature comparison |
| MYC | Proliferation-associated factor relevant to dedifferentiation and cancer | Cancer dedifferentiation transcriptomics |
| LGR5 | Intestinal stem cell marker used in regeneration studies | Stem cell ablation and regeneration models |
| CDX2 | Intestinal differentiation factor in dedifferentiation contexts | Intestinal regeneration models |
| HNF4A | Differentiation factor discussed in β-cell identity | Islet dedifferentiation studies |
| SLC2A2 | Glucose transporter linked to β-cell function and identity | Functional readout of β-cell state |
| UCN3 | Mature β-cell marker discussed in identity loss | Maturity marker in dedifferentiation assays |
How Is cell dedifferentiation Regulated?
Dedifferentiation is regulated by transcription factors, metabolic enzymes and epigenetic reprogramming. Ascl2 is required for dedifferentiation-driven regeneration of ablated intestinal stem cells. In diabetes, LDHA induces beta cell dedifferentiation through metabolic and epigenetic reprogramming. Loss of β-cell identity and dedifferentiation are described as not an irreversible process, implying that regulatory states can be reversed under some conditions. The process is also discussed in relation to FOXO1 signaling in diabetic β-cell failure.
cell dedifferentiation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LDHA | Diabetes, β-cell dedifferentiation via metabolic and epigenetic reprogramming | Knockout and overexpression in β-cell lines |
| SMOC1 | β-cell dedifferentiation in human islets | Knockout and overexpression in islet cell models |
| Ascl2 | Intestinal stem cell regeneration after ablation | Conditional knockout and overexpression in intestinal models |
| FOXO1 | Diabetic β-cell failure | Point-mutation and knockout models |
| INS | Loss of β-cell identity in diabetes | Knock-in reporter for identity tracking |
Diabetes and β-cell failure
Pancreatic β cell dedifferentiation is a mechanism of diabetic β cell failure, and loss of β-cell identity is observed in this context. Reviews emphasize that β-cell dedifferentiation in type 2 diabetes is an important concept, while asking what exactly it is. More recent work argues that loss of β-cell identity and dedifferentiation are not an irreversible process, which has therapeutic implications. LDHA has been shown to induce beta cell dedifferentiation in diabetes through metabolic and epigenetic reprogramming, and SMOC1 was identified as a β-cell dedifferentiation gene through human α-cell heterogeneity and trajectory inference.
Regenerative medicine and tissue repair
Ascl2-dependent cell dedifferentiation drives regeneration of ablated intestinal stem cells, demonstrating that dedifferentiation can be a physiological repair mechanism. This makes GO:0043697 relevant to strategies that aim to regenerate stem cell pools after injury.
Cancer biology
The role of dedifferentiation in cancer is debated. A direct contest of transcriptomic features compared cell dedifferentiation versus evolutionary reversal theories of cancer, highlighting the need for careful interpretation of dedifferentiation signatures.
From cell dedifferentiation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for dedifferentiation? | CRISPR knockout cell model |
| Does a specific mutation alter dedifferentiation capacity? | Point-mutation knock-in cell model |
| Can a stem-like reporter track dedifferentiation? | Knock-in reporter cell line |
| Does overexpression of a factor induce dedifferentiation? | Overexpression cell model |
| Which pathways regulate dedifferentiation? | CRISPR library screening with bioinformatics |
| Can dedifferentiated cells be redifferentiated? | Differentiation time-course in knockout or overexpression lines |
How to Study the cell dedifferentiation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcriptome changes | Identifying dedifferentiation signatures |
| Trajectory inference | Cell state transitions | Finding dedifferentiation genes such as SMOC1 |
| CRISPR knockout | Gene requirement | Testing Ascl2 or LDHA in dedifferentiation |
| Overexpression | Sufficiency of a factor | Inducing dedifferentiation in cell models |
| Epigenetic profiling | Chromatin and DNA methylation changes | Metabolic-epigenetic reprogramming by LDHA |
| Metabolic assays | Metabolic pathway activity | LDHA-driven dedifferentiation studies |
| Immunostaining | Protein identity markers | β-cell identity loss in diabetes models |
| Bioinformatics integration | Multi-omic interpretation | Prioritizing dedifferentiation candidates |
Transcriptomic profiling and trajectory inference
RNA-seq and trajectory inference analyses have been used to identify dedifferentiation genes, such as SMOC1 in human pancreatic α-cell heterogeneity studies. Transcriptomic feature comparisons have also been used to debate dedifferentiation versus evolutionary reversal theories of cancer.
Functional genetic screens
CRISPR-based screens and knockout models can test whether genes such as Ascl2 or LDHA are required for dedifferentiation. Ascl2-dependent dedifferentiation was demonstrated in intestinal stem cell regeneration after ablation.
Metabolic and epigenetic assays
Because LDHA induces beta cell dedifferentiation through metabolic and epigenetic reprogramming, metabolic assays combined with epigenetic readouts are appropriate for studying this axis.
Identity marker quantification
Loss of β-cell identity is assessed with markers such as INS, PDX1, NKX6.1, MAFA and UCN3 in diabetes dedifferentiation studies.
How CRISPR Can Be Used to Study GO:0043697 cell dedifferentiation
Knockout
CRISPR knockout cell models can test whether a gene is required for cell dedifferentiation. For example, Ascl2-dependent dedifferentiation drives regeneration of ablated intestinal stem cells, making Ascl2 a logical knockout target. LDHA knockout can test the metabolic-epigenetic axis of beta cell dedifferentiation.
Point Mutation
Point-mutation knock-in models allow testing of specific residues or variants in dedifferentiation genes. This is relevant for signaling factors such as FOXO1 in diabetic β-cell failure and for metabolic enzymes such as LDHA.
Knock-in
Knock-in reporters can track dedifferentiation states in live cells. Identity markers such as INS and stem cell markers such as LGR5 can be tagged to monitor loss of mature identity and reversion toward stem-like features.
Overexpression
Overexpression models test whether a candidate factor is sufficient to induce dedifferentiation. SMOC1 and LDHA are candidates for overexpression studies in islet cell models, while Ascl2 overexpression can be tested in intestinal regeneration contexts.
How EDITGENE Supports cell dedifferentiation Research
Researchers studying cell dedifferentiation-related genes often need to determine whether a candidate gene is causally involved in loss of mature identity or in regenerative reversion toward stem-cell features. Correlative expression data from RNA-seq and trajectory inference can nominate genes such as SMOC1, but causal testing requires precise genetic models.
Contact EDITGENE today to design your custom CRISPR model for cell dedifferentiation research.
Frequently Asked Questions About cell dedifferentiation
What is cell dedifferentiation (GO:0043697)?
Cell dedifferentiation is the process in which a specialized cell loses the structural or functional features that characterize it in the mature organism, or another relatively stable phase, and under certain conditions can revert toward the features of ancestral stem cells.
What genes are involved in cell dedifferentiation?
Reported genes include Ascl2 in intestinal stem cell regeneration, SMOC1 as a β-cell dedifferentiation gene, and LDHA in metabolic-epigenetic beta cell dedifferentiation.
Is cell dedifferentiation reversible?
Loss of β-cell identity and dedifferentiation are described as not an irreversible process, suggesting that redifferentiation may be possible under some conditions.
How is cell dedifferentiation related to diabetes?
Pancreatic β cell dedifferentiation is a mechanism of diabetic β cell failure, and β-cell dedifferentiation is an important concept in type 2 diabetes.
What is the role of Ascl2 in dedifferentiation?
Ascl2-dependent cell dedifferentiation drives regeneration of ablated intestinal stem cells.
What is the role of LDHA in beta cell dedifferentiation?
LDHA induces beta cell dedifferentiation in diabetes through metabolic and epigenetic reprogramming.
What is SMOC1 in β-cell dedifferentiation?
Human pancreatic α-cell heterogeneity and trajectory inference analyses revealed SMOC1 as a β-cell dedifferentiation gene.
Is dedifferentiation involved in cancer?
The role of dedifferentiation in cancer is debated, and transcriptomic features have been compared between cell dedifferentiation and evolutionary reversal theories of cancer.
How do researchers study cell dedifferentiation?
Researchers use RNA-seq, trajectory inference, CRISPR knockout, overexpression, metabolic assays and epigenetic profiling to study dedifferentiation.
What experimental models are used for cell dedifferentiation?
CRISPR knockout, point-mutation, knock-in reporter and overexpression cell models are used to test causal roles of dedifferentiation genes.
Conclusion
GO:0043697 cell dedifferentiation captures a fundamental plasticity process in which specialized cells lose mature features and can revert toward ancestral stem-cell states. It is essential for regeneration after stem cell ablation and is a mechanism of diabetic β-cell failure, with ongoing debate about its role in cancer. Causal dissection of genes such as Ascl2, SMOC1 and LDHA requires precise CRISPR models and integrated bioinformatics.
References
- 1. Murata K et al.. 2020. Ascl2-Dependent Cell Dedifferentiation Drives Regeneration of Ablated Intestinal Stem Cells.. Cell Stem Cell 26(3):377-390.e6 PMID: 32084390
- 2. Patel S et al.. 2024. Loss of β-cell identity and dedifferentiation, not an irreversible process?. Front Endocrinol (Lausanne) 15:1414447 PMID: 38915897
- 3. Talchai C et al.. 2012. Pancreatic β cell dedifferentiation as a mechanism of diabetic β cell failure.. Cell 150(6):1223-34 PMID: 22980982
- 4. Efrat S. 2019. Beta-Cell Dedifferentiation in Type 2 Diabetes: Concise Review.. Stem Cells 37(10):1267-1272 PMID: 31298804
- 5. Kang RB et al.. 2025. Human pancreatic α-cell heterogeneity and trajectory inference analyses reveal SMOC1 as a β-cell dedifferentiation gene.. Nat Commun 16(1):8434 PMID: 41057332
- 6. Li X et al.. 2026. LDHA induces beta cell dedifferentiation in diabetes through metabolic and epigenetic reprogramming.. Diabetologia 69(3):689-709 PMID: 41381887
- 7. Vinogradov AE et al.. 2025. "Cell dedifferentiation" versus "evolutionary reversal" theories of cancer: The direct contest of transcriptomic features.. Int J Cancer 156(9):1802-1813 PMID: 39888036
- 8. Weir GC et al.. 2013. β-cell dedifferentiation in diabetes is important, but what is it?. Islets 5(5):233-7 PMID: 24356710
